Sugi Predict

Sugi Predict / Targets / DDO

DDO

D-aspartate oxidase · Q99489 · DDO on Sugi Atlas →

5,039 patent compounds predicted against DDO, 3,221 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL3432805 SCHEMBL3432805 0.61 9/20
SCHEMBL3363456 SCHEMBL3363456 1.00 8/20
SCHEMBL3361024 SCHEMBL3361024 0.65 8/20
SCHEMBL3362656 SCHEMBL3362656 0.61 8/20
SCHEMBL3363129 SCHEMBL3363129 0.54 8/20
SCHEMBL3424908 SCHEMBL3424908 0.53 8/20
SCHEMBL3423807 SCHEMBL3423807 1.00 7/20
SCHEMBL3363264 SCHEMBL3363264 0.61 7/20
SCHEMBL3433397 SCHEMBL3433397 0.61 7/20
SCHEMBL3432869 SCHEMBL3432869 0.58 7/20
SCHEMBL3363859 SCHEMBL3363859 0.57 7/20
SCHEMBL3435254 SCHEMBL3435254 0.57 7/20
SCHEMBL3424009 SCHEMBL3424009 0.56 7/20
SCHEMBL3421760 SCHEMBL3421760 0.55 7/20
SCHEMBL3361211 SCHEMBL3361211 0.53 7/20
SCHEMBL3419432 SCHEMBL3419432 0.51 7/20
SCHEMBL3359175 SCHEMBL3359175 0.64 6/20
SCHEMBL3420670 SCHEMBL3420670 0.64 6/20
SCHEMBL3363037 SCHEMBL3363037 0.61 6/20
SCHEMBL3361286 SCHEMBL3361286 0.60 6/20

Clinical trials — most relevant to DDO by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
L-ornithine L-aspartate in Overt Hepatic Encephalopathy PHASE4COMPLETED
Minocycline for the Treatment of Early-Phase Schizophrenia PHASE3COMPLETED
L-Arginine in Pre-Eclampsia PHASE3COMPLETED
A Randomized, Clinical Trial of Vitamin E and Memantine in Alzheimer's Disease PHASE3COMPLETED
DAAOI-1 Treatment for Treatment-resistant Schizophrenia PHASE2COMPLETED
D-amino Acid Oxidase Inhibition (DAAOI-1) add-on Treatment for Chronic Schizophrenia PHASE2COMPLETED
Sodium Benzoate for Treatment of Attenuated/Transient Psychosis. A Randomized Placebo-controlled Trial. PHASE2WITHDRAWN
Treatment of Nodding Syndrome - A Randomized Blinded Placebo-Controlled Crossover Trial of Oral Pyridoxine and Conventional Anti-Epileptic Therapy, in Northern Uganda - 2012 PHASE2WITHDRAWN
Erythropoietin Therapy for Subarachnoid Hemorrhage PHASE2COMPLETED
BIRB 796 BS Versus Placebo in Patients With Moderate to Severs Plaque-type Psoriasis PHASE2COMPLETED
Treatment Study of Carnosine Versus Placebo in Gulf War Illness (GWI) PHASE2COMPLETED
Networked Drug REpurposing for Mechanism-based neuroPrOtection in Acute Ischaemic STROKE PHASE2UNKNOWN
A Pilot Clinical Trial With the Iron Chelator Deferiprone in Parkinson's Disease PHASE2COMPLETED
Diclofenac Dose Response Study PHASE1RECRUITING
A Study to Compare the Pharmacokinetics of Different Oral Formulations of FDL169 in Healthy Subjects PHASE1COMPLETED
D-aspartate and Therapeutic Exercise EARLY_PHASE1UNKNOWN
Targeting a Genetic Mutation in Glycine Metabolism With D-cycloserine EARLY_PHASE1COMPLETED
Prevalence of DAO (diamino Oxidase) Deficiency in Newborns nanCOMPLETED
In Vivo Assessment of Histamine Pharmacodynamics nanWITHDRAWN
Vancomycin Associated Red Man Syndrome (RMS) nanCOMPLETED
European Survey: Risk of Cyanide Poisoning in Smoke Inhalation nanCOMPLETED
Genetic DAO Deficiency and Lower Urinary Tract Symptoms nanCOMPLETED
Prognostic Value of (DHODH) Expression in (HGSOC): A Comparative Study Between Neoadjuvant and Adjuvant Chemotherapy Settings nanNOT_YET_RECRUITING
L-arginine add-on Therapy in Patients With Schizophrenia nanCOMPLETED
A Study on Risk Mutations of Vulnerability Genes of Schizophrenia nanUNKNOWN
Cerebral Oxygen Saturation and Cytochrome Oxidase REDOX State in Children With Epilepsy: A Pilot Study nanCOMPLETED
Prevalence of High Plasmatic 3OMethyldopa Level in a Specific Population of Patients With a Symptomatology Compatible With AADC Deficiency nanUNKNOWN
The Impact of Pharmacological and Electric Modulation of NMDA Pathway on the Cognitive Flexibility and Volitional Movement Preparation in Patients With Parkinson's Disease nanCOMPLETED
Mechanistic Studies of Teriflunomide in RRMS nanCOMPLETED
External Nitric Oxide Measurement Through SNO Degradation nanENROLLING_BY_INVITATION

Related proteins — ESM-2 sequence neighbours (a DDO binder may also engage these)

ProteinNameSimilarity
A3KCL7 — 0.999 A3KCL7 →
Q922Z0 — 0.995 Q922Z0 →
P31228 — 0.989 P31228 →
D3ZDM7 — 0.987 D3ZDM7 →
Q5R514 — 0.962 Q5R514 →
Q0V8R7 — 0.960 Q0V8R7 →
D3ZLY0 — 0.960 D3ZLY0 →
Q5U2W9 — 0.960 Q5U2W9 →
A7RDN6 — 0.958 A7RDN6 →
P13439 — 0.958 P13439 →
Q96NN9 — 0.958 Q96NN9 →
Q14CH1 — 0.958 Q14CH1 →
Q5E9T8 — 0.957 Q5E9T8 →
O95671 — 0.956 O95671 →
P22734 — 0.956 P22734 →
Q9UI17 — 0.956 Q9UI17 →
UMPS Uridine 5'-monophosphate synthase 0.956 landscape →
Q8QZR5 — 0.956 Q8QZR5 →
Q9Y5N5 — 0.956 Q9Y5N5 →
Q4V9J0 — 0.956 Q4V9J0 →
COMT Catechol O-methyltransferase 0.956 landscape →
Q96CB9 — 0.955 Q96CB9 →
Q8BGT5 — 0.955 Q8BGT5 →
P25409 — 0.955 P25409 →
Q29RU9 — 0.955 Q29RU9 →
Q8R164 — 0.954 Q8R164 →
Q9UBK8 — 0.954 Q9UBK8 →
Q3TY86 — 0.953 Q3TY86 →
Q9H867 — 0.953 Q9H867 →
Q6GM82 — 0.953 Q6GM82 →